NEW YORK (GenomeWeb) – Guardant Health today announced that it has partnered with the National Cancer Institute-funded SWOG cancer research consortium to identify mechanisms of resistance and future treatment options in non-small cell lung cancer patients.

The study, called SWOG-1403, will use Guardant's circulating tumor DNA test, Guardant 360, to examine whether combination EGFR blockade using cetuximab and afatinib is superior to afatinib alone as a frontline treatment for 600 patients with newly diagnosed EGFR-mutant NSCLC.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.